Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting

Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The Company highlighted the distinct ability of its AURIGIN™ platform to identify both cell state plasticity, the proliferative state in which cancer cells grow, and the causative gene targets. In a second poster, Auron shared preclinical data from its program targeting KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML). These data led to the nomination of AUTX-703, an orally available and selective KAT2A/B degrader development candidate, for which Auron expects to file an IND in 2024.